Blend compositions for oral administration as a rapidly dissolving powder and/or suspension
Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.
1. A free flowing dry powder oral formulation suitable for administration in each of an aqueous solution, aqueous dispersion, tablet, and powder dosage form,
wherein the formulation comprises an active pharmaceutical ingredient (API) in an amount from about 3% w/w to about 15% w/w, a surfactant or emulsifier in an amount from 0.1% w/w to 1% w/w, a galactomannan in an amount from about 0.05% w/w to about 0.5% w/w, one or more sweetening agents in an amount up to about 1.0% w/w, one or more diluents in an amount up to about 90% w/w, one or more flavoring agents in an amount from about 0.5% w/w to about 5% w/w and an organic acid in an amount from about 0.05% w/w to about 0.5% w/w, in a pharmaceutically acceptable preparation.
2. The formulation of claim 1 , wherein the API is a non-steroidal anti-inflammatory drug (NSAID).
3. The formulation of claim 1 , wherein the surfactant is an amphiphilic surfactant or emulsifier.
4. The formulation of claim 1 , wherein the galactomannan comprises fenugreek gum, guar gum, tara gum, locust bean gum, or any combination thereof.
5. The formulation of claim 1 , wherein the one or more diluents comprise isomalt, a dextrin, a maltodextrin, fructose, or any combination thereof.
6. The formulation of claim 1 , wherein the one or more flavoring agents comprise fruity or mint flavoring agents.
7. A free flowing dry powder oral formulation suitable for administration in each of an aqueous solution, aqueous dispersion, tablet, and powder dosage form,
wherein the formulation comprises an active pharmaceutical ingredient (API) in an amount from about 3% w/w to about 15% w/w, a galactomannan in an amount from about 0.05% w/w to about 0.5% w/w, one or more sweetening agents in an amount up to about 90% w/w, two or more flavoring agents in an amount from about 0.5% w/w to about 5% w/w and an organic acid in an amount from about 0.05% w/w to about 0.5% w/w, in a pharmaceutically acceptable preparation.
8. The formulation of claim 7 , wherein the API is a non-steroidal anti-inflammatory drug (NSAID).
9. The formulation of claim 7 , wherein the galactomannan comprises fenugreek gum, guar gum, tara gum, locust bean gum, or any combination thereof.
10. The formulation of claim 7 , wherein the galactomannan has a mannose to galactose ratio of from about 1:1 to about 4:1.
11. The formulation of claim 7 , wherein the sweeting agent comprises isomalt.
12. The formulation of claim 7 , wherein the two or more flavoring agents comprise fruity or mint flavoring agents.
13. The formulation of claim 12 , wherein the fruity or mint flavoring agents are selected from cherry, strawberry, and raspberry.
14. The formulation of claim 13 , wherein the surfactant or emulsifier is amphiphilic.
15. The formulation of claim 7 , wherein the formulation solubility or dispersability in water is no more than about 0.5 w/v.
16. The formulation of claim 7 , wherein the formulation is in a unit dosage container selected from the group consisting of a blister foil pack, stick pack, sachet, pouch, and bottle.
17. A free flowing dry powder oral formulation suitable for administration in each of an aqueous solution, aqueous dispersion, tablet, and powder dosage form,
wherein the formulation comprises a non-steroidal anti-inflammatory drug (NSAID) in an amount from about 6% w/w to about 10% w/w, a galactomannan in an amount from about 0.2% w/w to about 0.4% w/w, one or more sweetening agents in an amount up to about 90% w/w, one or more flavoring agents in an amount from about 0.5% w/w to about 5% w/w and an organic acid in an amount from about 0.1% w/w to about 0.2% w/w, in a pharmaceutically acceptable preparation.
18. The formulation of claim 17 , wherein the NSAID comprises ibuprofen, the galactomannan comprises guar gum, the one or more sweetening agents comprise isomalt, and the organic acid comprises citric acid.
19. The formulation of claim 18 , further comprising a surfactant or emulsifier in an amount from about 0.2% w/w to about 0.8% w/w.
20. The composition of claim 17 , wherein the formulation solubility or dispersability in water is no more than about 0.5 w/v.